SARAH SULLIVAN: Open Payments
NPI 1407856727 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 22 payments from 12 companies in 2025. Trend: 2023 $364 · 2024 $456 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 2 | $165 |
| ABBVIE INC. | 3 | $74 |
| PFIZER INC. | 4 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Amgen Inc. | 1 | $16 |
Products named: Dexcom G6 Transmitter, VRAYLAR, ELIQUIS, Kerendia, Veozah, GEMTESA, XIFAXAN, CAPLYTA.
Industry payments across MD — which companies pay providers there.
